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A pandemic of metabolic diseases, consisting of type 2
diabetes, nonalcoholic fatty liver disease, and obesity,
has imposed critical challenges for societies worldwide,
prompting investigation of underlying mechanisms and
exploration of low-cost and effective treatment. In this
report, we demonstrate that metabolic disorders in mice
generated by feeding with a high-fat diet without dietary
vitamin D can be prevented by oral administration of
polycationic amine resin. Oral administration of cholestyr-
amine, but not the control uncharged polystyrene, was
able to sequester negatively charged bacterial endotoxin
in the gut, leading to 1) reduced plasma endotoxin levels,
2) resolved systemic inflammation and hepatic steatohe-
patitis, and 3) improved insulin sensitivity. Gut dysbiosis,
characterized as an increase of the phylum Firmicutes
and a decrease of Bacteroidetes and Akkermansia muci-
niphila, was fully corrected by cholestyramine, indicating
that the negatively charged components in the gut are
critical for the dysbiosis. Furthermore, fecal bacteria
transplant, derived from cholestyramine-treated animals,
was sufficient to antagonize the metabolic disorders of
the recipient mice. These results indicate that the nega-
tively charged components produced by dysbiosis are
critical for biogenesis of metabolic disorders and also
show a potential application of cationic polystyrene to
treat metabolic disorders through promoting gut eubiosis.
Metabolic syndrome (MetS), in association with obesity,
fatty liver diseases, and type 2 diabetes, has imposed great
health challenges and an enormous economic burden on
societies worldwide (1,2). A key mechanism for MetS devel-
opment is insulin resistance, which is often generated by
chronic inflammation that attenuates insulin signal trans-
duction pathways, resulting in hyperglycemia and hyperlip-
idemia (3,4). Gut dysbiosis, showing increased Firmicutes
and reduction of Bacteroidetes, is critical for the biogenesis
of MetS and obesity (5–7). Bacteroidetes are Gram-negative
microbes, and their death may generate endotoxin, a highly
potent inflammatory component in the gut. On the other
hand, simple hepatic steatosis is benign, but ;20% of the
population with simple steatosis may further progress to
nonalcoholic steatohepatitis (NASH), characterized by he-
patic inflammation and liver fibrosis (8,9). To explain the
transition from simple steatosis to NASH, a “two-hit the-
ory” was proposed, suggesting that a second hit, such as
viral infection/xenobiotic exposure or others may drive the
pathophysiological progression (10).
Epidemic survey indicates association of vitamin D de-
ficiency with chronic liver diseases, obesity, and MetS (11–13).
Through animal models, we previously demonstrated that
vitamin D deficiency acts as a “second hit” to exacerbate the
impact of high-fat diet, leading to robust metabolic disorders
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with features of NASH (14). Recently, we showed that vita-
min D signaling through the induction of Paneth cell–
specific a-defensins maintains gut eubiosis to antagonize
MetS (15). Given the nature of positive charges by the
secretory form of a-defensins, we reasoned that applying
positively charged resins might have similar impacts.
RESEARCH DESIGN AND METHODS
Animal Treatment and Measurement
C57BL/6J mice (male, 4–6 weeks old) were fed either con-
trol chow (AIN93, containing 10–12% calories from fat
and 1,000 units/kg vitamin D3; HFK Bioscience) or vitamin
D–deficient high-fat diet (HD, 60% calories from fat and
without vitamin D supplement). After 10 weeks of feeding,
the mice fed with HD were divided into three groups (n = 10)
and subjected to 1) no treatment (HD), 2) cholestyramine
added to HD diet at 3% (weight for weight) (HD+CHOL), or
3) polystyrene treatment (HD+PS), for an additional
12 weeks. For fecal bacteria transplant (FBT), fresh donor
feces from cholestyramine or polystyrene treatments were
collected. After washing to remove the resins, ;4 3 108
colony-forming units of bacteria in 0.1 mL suspension
were administered by gavage to the recipient mice that had
been fed with either control chow or HD (n = 8–12) for
20 weeks. FBT was repeated once a week for a consecutive
8 weeks. Changing microbiota in the feces and ileal lumen
content was monitored by 16S rDNA-qPCR analysis. The
animal protocol followed the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Insti-
tutes of Health. The protocols for intraperitoneal glucose
tolerance test (IPGTT) and HOMA of insulin resistance
(HOMA-IR), fasting glucose, intestinal permeability, and
histological analysis were previously reported (15). A limu-
lus amebocyte extract kit (Chinese Horseshoe Crab Reagent
Manufactory, Xiamen, China) was used to detect plasma
lipopolysaccharide (LPS) content. Gene expression was de-
termined by qRT-PCR analysis and normalized to that of
RPL-19. Primer sequence information used for qPCR anal-
ysis is listed (Supplementary Tables 1 and 2).
In Vitro Sequestration of LPS by Cationic Resins
LPS (catalog no. L3012; Sigma-Aldrich) was dissolved in
pure water and specific adsorption was recorded at 258 nm.
Cholestyramine, polystyrene powder, and Pierce High Capac-
ity Endotoxin Removal Resin (catalog no. 88270; Thermo
Fisher Scientific) were mixed with LPS solution. The mixtures
were incubated for 1 h. After centrifuging at 500g for 1 min,
the supernatant was filtered through a 0.45-micron filter,
and adsorption was measured at 258 nm for the unbound
LPS. The experiment was repeated three times.
Gut Microbiota Analysis
The work was conducted at Novogene (Beijing, China). In
brief, mice were fed and treated with the following four
conditions: 1) control chow, 2) HD, 3) HD+CHOL, or 4)
HD+PS for 12 weeks (n = 5 for each condition). The fecal
microbe DNA was extracted using the stool DNA kit
(Omega, China) method. Details can be found in our pre-
vious work (15).
Statistical Analysis
Data recording, processing, and calculating were completed
using Microsoft Excel 2003 and GraphPad Prism 5.0. Data
were plotted as mean 6 SEM. Comparisons across groups
were assessed using a Student t test or one-way ANOVA,
followed by Tukey multiple comparison testing. Statistical
significance was performed as *P , 0.05 or **P , 0.01.
RESULTS
Metabolic Disorders in Mice Are Resolved by Oral
Administration of Cholestyramine Through
Sequestrating Gut Endotoxin
As expected, the mice fed HD gained substantial weight
together with increased visceral fat accumulation com-
pared with those fed with control diet (Fig. 1A and B). The
mice fed with HD developed glucose intolerance and insulin
resistance, as indicated by elevation of fasting blood glucose,
abnormal IPGTT, and a high level of HOMA-IR values (Fig.
1C–E). Likewise, dyslipidemia was observed in the HD mice,
showing increased levels of serum total cholesterol, triglyc-
eride, nonesterified fatty acids, and LDL cholesterol (LDL-C)
(Fig. 1F). Nevertheless, all the features of metabolic disor-
ders were significantly improved with oral administration of
cholestyramine (HD+CHOL). On the other hand, uncharged
polystyrene beads were without significant impact. Importantly,
these results indicated the presence of “negatively charged
components” in the gut as causative factors in the insulin
resistance and metabolic disorders in the murine model.
Emerging evidence showed plasma endotoxin is critically
related to MetS and NASH, suggesting a potential causal
relationship (4,16,17). Indeed, the plasma endotoxin levels
were elevated approximately twice in the HD-fed mice as in
the control mice (Fig. 1G). As expected, the plasma endo-
toxin levels were substantially reduced through oral admin-
istration of cationic polystyrene, whereas polystyrene beads
were without effect. The elevated plasma endotoxin may fur-
ther trigger systemic inflammation that can subsequently in-
duce insulin resistance. Indeed, TNF-a levels in the plasma,
being elevated under HD feeding, were declined through
cationic polystyrene treatment (Fig. 1H). Finally, through
an in vitro binding assay, we confirmed that cholestyramine
could effectively deplete endotoxin (Fig. 1I).
NASH Features Are Ameliorated by Cholestyramine
Treatment
Hepatic steatosis and nonalcoholic fatty liver disease scores
were evident in the parenchyma of the mice fed with HD
(Fig. 2A and B). Moderate but evident fibrosis was present,
as demonstrated by Masson’s trichrome staining (Fig. 2C)
and the mRNA levels of liver collagen-a1 (Coll-a1) (Fig. 2D)
in mice subjected to HD feeding for 22 weeks. Hepatic
inflammation was further demonstrated by the presence
of CD3+ T cells (Fig. 2E and F) and increased expression of
inflammatory cytokines such as TNF-a, arginase 1, and in-
ducible nitric oxide synthase (iNOS) (Fig. 2G–I). The
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remarkable elevation of serum alanine aminotransferase
(ALT) (Fig. 2J) as an indicator of hepatic injury was also
evident in the HD mice. Importantly, all of these NASH
lesions were completely prevented by oral administration
of cholestyramine, whereas polystyrene resin was without
the effects. These results again imply the existence of nega-
tively charged components in the gut that may impact the
hepatocytes for steatosis and hepatic stellate cells for fibrosis
in the HD-fed mice.
Small Intestinal Inflammation and Permeability Are
Ameliorated by Cholestyramine
The pathological findings in the liver could be mediated
through impaired enterohepatic circulation. As expected,
the mice fed HD exhibited inflammation in the ileum, as
indicated by the expression of two proinflammatory cytokines
(Supplementary Fig. 1A and B). The inflammation-exerted
intestinal lesion was also demonstrated by the increased
gut permeability (Supplementary Fig. 1C). Furthermore,
the increment of gut permeability was associated with de-
creased expression of tight-junction components, including
ZO1, claudin 2, and occludin by HD-fed mice (Supplemen-
tary Fig. 1D). Expression of muc2, a major gene for intes-
tinal mucus, was also downregulated, leading to impairment
of mucus in the ileum (Supplementary Fig. 1E–G). Im-
portantly, oral administration of cholestyramine, but not
polystyrene, substantially antagonized the aforementioned
Figure 1—Metabolic disorders in the mice fed with HD are resolved by oral administration of cholestyramine. C57/B6 mice were fed with control
chow (Ctrl, AIN93, containing vitamin D3 1,000 IU/kg) or HD (60% calories from fat without vitamin D supplement) for 22 weeks, as a negative and
positive control, respectively. For the treatment groups, the mice were initially fed with HD for 10 weeks. Then cholestyramine or polystyrene at
3% (weight for weight) was added in the HD diet, as HD+CHOL and HD+PS, respectively (n = 10). A: Time course of changing body mass (n = 10).
B: Visceral fat coefficient, the percentage of visceral fat mass over the body mass. C: Fasting blood glucose (12 h), n = 10. D: IPGTT and area
under the curve (AUC) for the mice after 20 weeks of feeding, n = 6. E: HOMA-IR after 20 weeks feeding. F: Serum total cholesterol, serum total
triglyceride, serum nonesterified fatty acids (NEFA), and serum LDL-C. G: The levels of plasma endotoxin (LPS), n = 5. EU, endotoxin units.
H: The levels of serum TNF-a, n = 5. I: In vitro sequestration of plasma LPS levels by cholestyramine (CHOL), polylysine cellulose resin (Poly-Lys),
and polystyrene (PS). Each experiment was repeated three times. * or #, P < 0.05; ** or ##, P < 0.01; ***P < 0.001. * and **Comparisons were
made against the HD group. For panels A–H, comparisons were also made between the HD-CHOL and HD-PS groups. # and ##Comparisons
were made against the HD+CHOL group. For panel I, the in vitro endotoxin depleting experiment, the comparisons were made for sequestration
efficacy within each type of resin. Data were mean 6 SEM.
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intestinal lesions. Again, these results demonstrated that
the negatively charged pathogenic components might cause
intestinal injury and subsequent fatty liver.
Gut Dysbiosis Is Resolved by Cholestyramine Treatment
The elevation of plasma endotoxin by the HD feeding may come
from gut dysbiosis and the impairment of intestinal interface.
For the control chow feeding, Bacteroidetes at the phylum level
was dominant over Firmicutes (Fig. 3A). In contrast, the abun-
dance of Bacteroidetes was declined, whereas the abun-
dance of Firmicutes was greatly increased in the mice fed
with HD. The results were in agreement with the clinical
findings, showing increased Firmicutes and decreased Bac-
teroidetes in obese patients (7,18). Importantly, cholestyr-
amine treatment restored eubiosis, showing reduction of
Firmicutes and restoration of Bacteroidetes. Restoration
of Bacteroidetes, a major group of Gram-negative microbes
that generate endotoxin at their death, is in agreement with
the reduction of plasma endotoxin levels by cationic beads.
Symbiotic Akkermansia muciniphila, which accounts for
;8% of fecal bacteria for the control chow-fed mice, was
decreased to 3% by the HD feeding. Cholestyramine treat-
ment restored the A. muciniphila to a ratio of 6% among the
total bacteria. We also examined the microbiota within ileum
in the mice under the treatments. We applied 16S rDNA
high-throughput sequencing to examine the gut microbiota.
Through hierarchical clustering (Fig. 3B and C), closely similar
gut microbiota appeared grouped together in two states: gut
microbiota from the mice treated with cholestyramine were
closely related to those in the control feeding, and the
microbiota from the mice treated with polystyrene were
closely related to the ones from the HD feeding. Again,
the increase in phylum Firmicutes by HD feeding was sup-
pressed by cholestyramine treatment. The loss of Bacteroidetes
and A. muciniphila by the mice fed with HD was restored
with cationic polystyrene treatment (Fig. 3D and E).
Microbes Derived From the Cholestyramine Treatment
Are Sufficient to Antagonize the Metabolic Disorders of
the Recipients
Given the fact of restoring of eubiosis and reduction of
plasma endotoxin by cationic administration, we asked if
Figure 2—NASH features are antagonized by cholestyramine treatment. The liver tissues and serum ALT levels of the mice described in Fig. 1
were assessed for NASH characteristics. A: Hematoxylin-eosin (H&E) staining. B: Hepatic steatosis and lesions were assessed for NASH based on
H&E staining. C: Masson’s trichrome staining for liver fibrosis. D: Hepatic gene expression of Coll-a1, n = 6–7. E and F: Immunohistochemical
staining of T-cell marker CD3 of liver tissue. CD3+ cell number counting on liver tissue stained with CD3 (3400-fold). Liver inflammation as measured
by gene expression of TNF-a (G), arginase 1 (H), and iNOS (I), n = 4–6. J: Serum ALT levels, n = 8–10. *P < 0.05; **P < 0.01; ***P < 0.001. * and
**Comparisonsweremade against theHDgroup. # and ##Comparisonsweremade against theHD+CHOLgroup. Dataweremean6 SEM. Ctrl, control.
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the rebalanced gut microbiota was sufficient to antago-
nize the MetS. We performed FBT with two types of fecal
microbes, one from cationic polystyrene and another from
HD diet. Results showed that the gut microbiome derived
from the cationic polystyrene-treated mice reduced body
weight and visceral fat deposition of the recipients (Fig. 4A
and Supplementary Fig. 2B). Likewise, IPGTT, fasting blood
glucose, plasma cholesterol, and LDL were all suppressed,
and the HLD-to-LDL ratio was restored to normal levels after
FBT of the microbes derived from cationic polystyrene-
treated animals (Fig. 4B–E). Liver injury (serum ALT), mac-
rovesicular steatosis, and fibrosis of the recipients were re-
lieved by FBT derived from cholestyramine treatment (Fig.
4F–I). Finally, our data showed that FBT could actually
change the structure of the microbiota within the distal
region of the small intestine of the recipients (Supplemen-
tary Fig. 3).
DISCUSSION
Epidemiological surveys and animal experiments show that
high calories may not be sufficient to account for biogenesis
of metabolic disorders, indicating that additional second
hits are needed. Gut dysbiosis was overwhelming in the
metabolic disorders, showing elevation of phylum Firmi-
cutes and downregulation of phylum Bacteroidetes, the
major Gram-negative bacteria. We thus reasoned that the
reduced abundance of Bacteroidetes might be due to their
death, which consequently elevates intestinal and plasma
endotoxin, promoting insulin resistance and even NASH. In
addition to its original designation as bile acid sequestrant
to reduce plasma cholesterol, cholestyramine was found to
Figure 3—Gut dysbiosis is rebalanced through cationic polystyrene treatment. The microbiota in the ileum and feces of the mice described in
Fig. 1 was examined. A: The abundances of phyla Firmicutes (Firm) and Bacteroidetes (Bact), species A. muciniphila (Akk), and class Gam-
maproteobacteria (g-proteo) in the feces were detected by 16S rDNA-qPCR (n = 6 for each group). B: The bacteria population in the lumen of
ileum was determined by high-throughput sequencing analysis (n = 5 for each group). UPGMA (unweighted pair-group method with arithmetic
mean) clustering based on weighted unifrac distance of the top 10 relative abundant phyla. C: NMDS (non-metric multidimensional scaling) plot;
every point shows one mouse, different colors signify different groups, and the stress = 0.127. D: The relative abundance of bacteria at phylum
levels in the ileal lumen. E: The relative abundance of A. muciniphila in the ileal content. Ctrl, control.
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promote GLP-1 expression through activation of TGR5, a G
protein–coupled receptor for bile acids (19). A small-sized
clinical study showed that colestimide could improve
NASH, but the underlying mechanism is unknown
(20). Another clinical study applied bile acid sequestrant
to treat patients with type 2 diabetes (21). The authors
found that the bile acid levels were not correlated with
the efficacy of the treatment, which raises a question for
the actual role of bile acid sequestration in the treatment.
The mechanism for the cationic resin–mediated restoration
of eubiosis is unknown. However, the critical role of the
positive charges of the resin indicates that the negatively
charged endotoxin along with other microbe products, such
as DNA fragments, and short-chain fatty acids may be crit-
ical as well. Another interesting question that should be
further addressed is how A. muciniphila, a major symbiotic
species that has the power to antagonize metabolic disor-
ders in the gut, is substantially recovered in the gut by
cationic resin treatment.
Conclusion
We found that oral administration of cationic resin, such as
cholestyramine, can thoroughly reduce plasma endotoxin,
promotes the gut eubiosis, resolves inflammation, restores
insulin responsiveness, and antagonizes hepatic steatosis
and fibrosis. Moreover, FBT demonstrated that the reba-
lanced gut microbes from the cholestyramine-treated ani-
mal were sufficient to reverse the metabolic disorders, again
showing critical roles of gut microbes in maintaining health.
Our findings also provide preclinical justification for clinical
trials for treatment of NASH and MetS through cationic
polymers to sequestrate the dysbiosis that produced neg-
atively charged components in the gut.
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treatment. C: Fasting blood glucose of the mice at the end of FBT treatment. D: Plasma cholesterol. E: Plasma LDL-C. F: Serum ALT levels for
liver injury. G: Hematoxylin-eosin (H&E) staining of liver tissues for hepatic steatosis; Masson’s trichrome staining of liver tissues for fibrosis;
immunohistological staining of CD3+ lymphocytes for liver inflammation of the mice at the end of FBT. H: Liver inflammation was assessed
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